Note: Adamas Pharmaceuticals's revenues are gauged from an analysis of company filings.
Trademark applications show the products and services that Adamas Pharmaceuticals is developing and marketing.
Adamas Pharmaceuticals doesn't have any recent trademark applications, indicating Adamas Pharmaceuticals is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
KOBILTI Pharmaceuticals for the treatment of nervous system disorders
KOTIMLI Pharmaceuticals for the treatment of nervous system disorders
ZIMRALI Pharmaceuticals for the treatment of nervous system disorders
Determine whether Adamas Pharmaceuticals grew or shrank during the last recession. This is useful in estimating the
financial strength and credit risk of the company.
Compare how recession-proof Adamas Pharmaceuticals is relative to the industry overall.
While a new recession may strike a particular industry, measuring the
industry and company's robustness during the last recession estimates its ability to weather future recessions.
Market Share of Adamas Pharmaceuticals's Largest Competitors
A competitive analysis shows these companies are in the same general field as Adamas Pharmaceuticals, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Adamas Pharmaceuticals.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Adamas Pharmaceuticals and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.